Background and Purpose: The blood-brain barrier (BBB), a critical interface of specialized endothelial cells, plays a pivotal role in regulating molecular and ion transport between the central nervous system (CNS) and systemic circulation. Experimental Approach: This review aims to delve into the intricate architecture and functions of the BBB while addressing challenges associated with delivering therapeutics to the brain. Historical milestones and contemporary insights underscore the BBB's significance in protecting the CNS. Key Results: Innovative approaches for enhanced drug transport include intranasal delivery exploiting olfactory and trigeminal pathways, as well as techniques like temporary BBB opening through chemicals, receptors, or focused ultrasound. These avenues hold the potential to reshape conventional drug delivery paradigms and address the limitations posed by the BBB's selectivity. Conclusion: This review underscores the vital role of the BBB in maintaining CNS health and emphasizes the importance of effective drug delivery through this barrier. Nanoparticles emerge as promising candidates to overcome BBB limitations and potentially revolutionize the treatment of CNS disorders. As research progresses, the application of nanomaterials shows immense potential for advancing neurological therapeutics, albeit with careful consideration of safety aspects.
Objective. Quinolone moiety is an important class of nitrogen containing heterocycles widely used as key building blocks for medicinal agents. It exhibits a wide spectrum of pharmacophores and has bactericidal, antiviral, antimalarial, and anticancer activities. In view of the reported antimicrobial activity of various fluoroquinolones, the importance of the C-7 substituents is that they exhibit potent antimicrobial activities. Our objective was to synthesize newer quinolone analogues with increasing bulk at C-7 position of the main 6-fluoroquinolone scaffold to produce the target compounds which have potent antimicrobial activity.Methods. A novel series of 1-ethyl-6-fluoro-4-oxo-7-4-[2-(4-substituted phenyl)-2-(substituted)-ethyl]-1-piperazinyl-1,4-dihydroquinoline-3-carboxylic acid derivatives were synthesized. To understand the interaction of binding sites with bacterial protein receptor, the docking study was performed using topoisomerase II DNA gyrase enzymes (PDB ID: 2XCT) by Schrodinger’s Maestro program.In vitroantibacterial activity of the synthesized compounds was studied and the MIC value was calculated by the broth dilution method.Results. Among all the synthesized compounds, some compounds showed potent antimicrobial activity. The compound8gexhibited good antibacterial activity.Conclusion. This investigation identified the potent antibacterial agents against certain infections.
3 October 2018 in Current Computer-Aided Drug Design
1,6-Dihydropyrimidine exerts notable pharmacological efficiency and emerged as integral backbones for treatment of type-II diabetes mellitus. To optimize the in vitro and in-silico study we carried out on substituted 1,6-Dihydropyrimidine. The objective of the present study is to evaluate the binding interaction of 1,6-Dihydropyrimidine compounds with protein tyrosine phosphatase (PTP1B) enzyme and also check ADME/T properties of best scored compounds. The in-silico study (docking) was carried out through target protein tyrosine phosphatase (PTP1B) retrieved from protein data bank having PDB ID: 2QBS and the anti diabetic activity of the test compounds was tested against protein tyrosine phosphatase (PTP1B) enzyme by using Calbiochem® PTP1B colorimetric assay kit. The results of molecular Docking revealed that, with respect to their free binding energy 6A, 3K, 1B and 2K compounds have the lowest binding energy compared to positive control. In-silico ADME/T predictions revealed that all best scored compounds had good absorption as well as solubility characteristics through substrate binding sites. After conducting the in vitro studies it was observed that compounds having -3NO2, 3,4-OCH3 ,4-NO2 and 4-Cl substitution on phenyl ring in the basic moiety shows good anti diabetic activity The present computational approach provided valuable information on the binding process of 1,6-Dihydropyrimidine compounds to the binding site of PTP-1B. These compounds may serve as potential lead compound for developing new 1,6-Dihyropyrimidine as a promising anti diabetic agent.
Simple, rapid, sensitive, robust, and validated high-performance thin-layer chromatography was developed for the simultaneous determination of anti-diabetic drugs Teneligliptin hydrobromide (TH) and Metformin hydrochloride (MH) in bulk and pharmaceutical formulation. HPTLC system equipped Camag Linomat V, TLC Scanner IV, Twin Trough chamber, Dual-wavelength UV Cabinet, and win CATS software V1.4.7 were used during the study. Separation of analytes were achieved using a pre-coated silica gel G60 F254 aluminum Sheets 10×10 cm2, with the thickness of 0.2 mm as stationary phase and a mobile phase comprising of Methanol: Ammonium sulfate (0.5 %w/v): Triethylamine (9: 2.7: 0.5 v/v/v). The detection wavelength was set at 237 nm. The Rf value of the TH and MH was 0.63 and 0.19, respectively. The method was validated using a dynamic linear range of 4-28 ng/band and 100-700 ng/band for TH and MH, respectively. The developed method was validated as per the ICHQ2 (R1) guideline. The statistical analysis proved that the method is accurate with 98.80–99.38 % w/v and 99.66–99.96 % w/v for TH and MH, respectively, and precise with less than 2 % RSD. The Plackett-Burman design was applied to check the robustness of the developed method. Finally, the method is termed as linear, precise, accurate, and robust. It can be implemented successfully for the routine analysis of pharmaceutical dosage forms comprising TH and MH and is appropriate for regulatory submission under regulatory flexibility.